Skip to main content

Day: August 12, 2021

Simmons Receives Federal Reserve Approval for Pending Acquisitions of Landmark Community Bank and Triumph Bancshares, Inc.

PINE BLUFF, Ark., Aug. 12, 2021 (GLOBE NEWSWIRE) — Simmons First National Corporation (NASDAQ: SFNC) (the “Company” or “Simmons”) announced today that the Federal Reserve Bank of St. Louis (“Federal Reserve”) has approved Simmons Bank’s applications for its proposed acquisitions of Landmark Community Bank (“Landmark”) based in Collierville, Tennessee, and Triumph Bank, the bank subsidiary of Triumph Bancshares, Inc. (“Triumph”), based in Memphis, Tennessee. The Federal Reserve also accepted Simmons’ waiver request with respect to its application for its proposed acquisition of Triumph. “We are pleased to receive Federal Reserve approval of our acquisitions of Landmark and Triumph that will enhance our scale in the Memphis and Nashville markets, accelerate our growth trajectory and drive long-term shareholder value,” said George...

Continue reading

Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing Trial start-up activities to support non-melanoma skin cancer indications underway Multiple clinical data readouts anticipated in 2022 CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced second quarter 2021 financial results and provided a business update. “We remain excited about the prospects for vidutolimod in melanoma, based upon compelling clinical data to date, as well as our expansion into new tumor types. We are focused squarely on execution of our clinical trials to deliver upon these opportunities,...

Continue reading

OMNIQ Announces Record Six Months Revenue of $33M, a 24% Growth YoY and Second Quarter 3.5% Growth to $13.1M

Subsequent to quarter end, OMNIQ announced the closing of its 51% acquisition of technology leader, Dangot Computers Ltd (Dangot). Based on 2020 results creating a combined $91 Million Revenue provider of automation and object identification solutions, positioned to drive increased adoption of OMNIQ’s AI Based Offerings. OMNIQ will start consolidating Dangot’s Financial Results beginning July 1, 2021. Growth in Revenue of OMNIQ and Dangot in H1 2021 result in a $52.5 Million Dollar Consolidated Revenue of the combined Company – an annual run rate exceeding $100 Million a year.SALT LAKE CITY, Aug. 12, 2021 (GLOBE NEWSWIRE) — OMNIQ Corp. (OTCQB: OMQS) (“OMNIQ” or “the Company”), a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, today announced its financial results for the three month period...

Continue reading

Phunware Reports Second Quarter 2021 Financial Results

AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) — Phunware, Inc. (NASDAQ: PHUN) (“Phunware” or “the Company”), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, today announced financial results for its second quarter ended June 30, 2021. “We were extremely encouraged by the continued operational momentum for our business during Q2 despite the ongoing pandemic, as we further accelerated our MaaS platform vision and adoption across a number of key fronts including new product introduction and indirect channel expansion,” said Alan S. Knitowski, President, CEO and Co-Founder of Phunware. “Not only have we formally rolled out our entire blockchain-enabled Mobile Loyalty Ecosystem specific to PhunToken, PhunCoin and PhunWallet on a direct-to-consumer basis...

Continue reading

Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results

AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2021. “We continue to make progress on advancing our wholly owned pipeline of next-generation ETBs and our existing partnerships. We reached an important milestone recently with initiation of clinical development of MT-6402 (targeting PD-L1 via dual mechanisms) which is the first of our third generation ETBs to enter the clinic,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive and Scientific Officer. “With regard to TAK-169, we are now looking forward to continuing clinical development,...

Continue reading

EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended June 30, 2021 and provided an update on recent corporate and operational activities. “In the second quarter of 2021 we made significant advancements to build our business and our clinical initiatives remain on track as we enter this new phase of continued growth,” said Brian Strem, Ph.D., President and Chief Executive Officer of EyeGate. “We took important steps to advance our pipeline programs for PP-001 and OBG, and we look forward to leveraging new opportunities to expand the therapeutic...

Continue reading

DCP Midstream to Participate in 2021 Citi One-on-One Midstream & Energy Infrastructure Conference

DENVER, Aug. 12, 2021 (GLOBE NEWSWIRE) — DCP Midstream, LP (NYSE: DCP) announced that Wouter van Kempen, chairman, president, and chief executive officer and Sean O’Brien, group vice president and chief financial officer will conduct a series of virtual meetings with investment community representatives at the 2021 Citi One-on-One Midstream & Energy Infrastructure Conference on August 18, 2021. The materials to be used at this conference will be posted to the Investors section of DCP Midstream’s website at www.dcpmidstream.com on August 17, 2021. ABOUT DCP MIDSTREAM, LP DCP Midstream, LP (NYSE: DCP) is a Fortune 500 midstream master limited partnership headquartered in Denver, Colorado, with a diversified portfolio of gathering, processing, logistics and marketing assets. DCP is one of the largest natural gas liquids producers...

Continue reading

Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and six months ended June 30, 2021 and provided a business update. Business Operations Update:  The Company is conducting, supporting, and planning multiple clinical trials of eprenetapopt (APR-246) and APR-548. On August 4, 2021, the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the clinical trials of eprenetapopt in combination with azacitidine in our myeloid malignancy programs. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine in our myeloid malignancy programs, which...

Continue reading

Mercury Systems receives $17M order for advanced data transfer systems

ANDOVER, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a leader in trusted, secure mission-critical technologies for aerospace and defense, announced it received a $17 million order from the U.S. Naval Air Warfare Center’s Aircraft Division (NAWC-AD) for Advanced Data Transfer Systems (ADTS) for deployment across multiple rotary-wing and tilt-rotor platforms. The ADTS, a rugged data, video, and audio loader and recorder with cybersecurity capability, is used for moving mission data securely to and from the aircraft for pre- and post-mission analysis. The order is part of a firm-fixed-price, indefinite delivery/indefinite quantity (IDIQ) contract award worth up to $84.9 million originally received in September 2020 by Physical Optics Corporation, recently acquired by Mercury Systems....

Continue reading

Brookfield Business Partners Announces Renewal of Limited Partnership Unit Normal Course Issuer Bid

BROOKFIELD, NEWS, Aug. 12, 2021 (GLOBE NEWSWIRE) — Brookfield Business Partners L.P. (NYSE: BBU) (TSX: BBU.UN) (“Brookfield Business Partners”) today announced that the Toronto Stock Exchange (the “TSX”) has accepted a notice filed by Brookfield Business Partners of its intention to renew its normal course issuer bid for its limited partnership units (the “units”). Brookfield Business Partners believes that in the event the units trade in a price range that does not fully reflect their value, the acquisition of units may represent an attractive use of available funds. Under the normal course issuer bid, the Board of Directors of the general partner of Brookfield Business Partners authorized the partnership to repurchase up to 5% of the total issued and outstanding units, or 3,929,206 units. At the close of business on August 10,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.